Delivers up-to-date industry news on topics like drug approvals, product recalls, company expansions and acquisitions, market trends for all OSD forms, as well as excipients, packaging and supply chain issues. Monitors market trends in specific drug categories as well as in supplements/nutraceuticals. Provides updates on clinical trials. Includes alerts about new or upcoming regulatory issues.
The U.S. Food and Drug Administration approved Vowst, the first fecal microbiota product that is taken orally. Vowst is approved for the prevention of recurrence of Clostridioides difficile (C. difficile) infection (CDI) in individuals 18 years of age and older, following antibacterial treatment for recurrent CDI.
read more
Bacterial infections are known to be one of the leading causes of deaths, worldwide. In fact, infections caused by bacteria are responsible for every one out of eight deaths, globally. This is because most pathogenic bacteria have developed resistance against the commonly prescribed therapies.
read more
The global cancer pain management market is predicted to hit over $7.80B by 2030, at a CAGR of 5.25% during the forecast period, according to a report by Research & Markets.
read more
The global pharmaceutical excipients market size is estimated to increase by $3.83B from 2022 to 2027. The market's growth momentum will progress at a CAGR of 6.54% during the forecast period, according to a report by Technavio. Increasing demand for functional excipients is the main driver.
read more
The global lactase market is estimated to be valued at $247M in 2022. It is projected to reach $336M by 2027, at a CAGR of 6.3%, in terms of value, between 2022 and 2027, according to a study by Research & Markets.
read more
The idiopathic pulmonary fibrosis treatment market size is forecasted to increase by $1.361B from 2022 to 2027, accelerating at a CAGR of 6.68%, according to a study by Technavio. The growth will be driven by the increasing prevalence of respiratory diseases, the growing geriatric population, and the increase in the number of smokers.
read more
Colorcon Inc. announces Nutracore™, a range of label friendly materials for tablets and capsules specially designed to meet the technical and commercial needs of nutraceutical and supplement providers.
read more
Roquette, a provider of plant-based ingredients and pharmaceutical and nutraceutical excipients, opened a pharmaceutical innovation center, near Philadelphia. Staffed with a team of research, application and formulation experts, the $25M center will be a training and collaboration hub for pharmaceutical and nutraceutical manufacturers around the ...
read more
IFF, a manufacturer of functional ingredients, excipients and flavors for dietary supplements, pharmaceutical products, and biotechnology, announced the launch of a pectin-based technology, a further expansion of its vegan softgel offering.
read more
AbbVie announced that the U.S. Food and Drug Administration (FDA) has approved expanding the indication of QULIPTA® (atogepant) for the preventive treatment of migraine in adults.
read more
The pulmonary arterial hypertension (PAH) drugs market size is forecasted to increase by $2,080M from 2022 to 2027, at a CAGR of 6.62%, according to a study by Technavio. The growth of the market will be driven by the immunity-boosting properties of herbal medicines, low side effects, and natural healing by using herbal remedies.
read more
The global stomach cancer treatment market is anticipated to witness impressive growth through 2028, according to a study by Research & Markets. This can be ascribed to the growing development of novel drugs and therapies for treating stomach cancer.
read more
The empty capsules market is forecast to increase by $1.10B from 2021 to 2026, at a CAGR of 7.3%, according to a study by Technavio. The growth will be driven by the increasing applications in the pharmaceutical industry, technological advances in empty capsules, and the growing geriatric population.
read more
The narcolepsy drug market size is forecasted to increase $1.60B from 2021 to 2026, at a CAGR of 9.1%, according to a report by Technavio. The growth of the market will be driven by the rising number of product launches and clinical trials, the increasing incidence of narcolepsy in adults, and the growing number of studies to understand the cause ...
read more
The obsessive-compulsive disorder drugs market size is forecast to increase by $266.78M from 2021 to 2026, at a CAGR of 5.55%, according to a study by Technavio. The growth of the market will be driven by the rising prevalence of OCD, the launch of new molecules, and awareness programs for OCD.
read more